Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease
NCT03997097 · University Hospital, Montpellier · PHASE3 · withdrawn · last registry update 2023-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “New sponsor” | – | Registry record, University Hospital, Montpellier |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-22Phase 3 first posted: University of Alabama at Birmingham, Sildenafil 50 mg Oral Tablet + Placebo Oral Tablet (NCT06377098)
- 2024-02-28Also stopped (terminated): Uniformed Services University of the Health Sciences, Sildenafil Citrate 50Mg Tab + Gadolinium contrast infusion (NCT04058132)
- 2024-02-20Also stopped (terminated): Nanjing First Hospital, Nanjing Medical University, Sildenafil (NCT02284737)
- 2024-01-11Also stopped (terminated): Baylor College of Medicine, Pentoxifylline (NCT01774487)
- 2023-11-13Results posted on the registry: Actelion, FDC macitentan/tadalafil + Macitentan 10 mg (NCT03904693)
- 2023-11-08Phase 3 first posted: University Hospital, Rouen, Sildenafil (NCT06123156)
- 2023-11-07Also stopped (terminated): Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2023-10-31Results posted on the registry: University of Mississippi Medical Center, Sildenafil 100 mg + Bosentan 125 mg (NCT04770155)
- 2023-10-31Also stopped (terminated): University of Mississippi Medical Center, Sildenafil 100 mg + Bosentan 125 mg (NCT04770155)
- 2023-10-12Results posted on the registry: Baylor College of Medicine, Pentoxifylline (NCT01774487)
- 2023-10-04Also stopped (terminated): Legacy Health System, Trental Pill (NCT03916068)
- 2023-09-26Phase 3 first posted: Sunnybrook Health Sciences Centre, modified PENTOCLO (mPENTOCLO) + sham mPENTOCLO (NCT06055257)
- 2023-09-21Results posted on the registry: Futura Medical Developments Ltd., Tadalafil 5mg (Male) + Tadalafil 5mg (Female) (NCT04984993)
- 2023-09-15Phase 3 first posted: University of Brasilia, Miltefosine 50mg + Pentoxifylline 400mg (NCT06040489)
- 2023-09-14Results posted on the registry: University of Cincinnati, Trental (NCT01508221)
- 2023-08-15Also stopped (withdrawn): University of Nebraska, Sildenafil citrate (NCT00871065)
- 2023-08-02Phase 3 first posted: Beni-Suef University, tadalafil + Sildenafil (NCT05971667)
- 2023-07-20Phase 3 first posted: Mansoura University, Tadalafil 5mg / Placebo (NCT05955001)
- 2023-07-19Phase 3 first posted: Beni-Suef University, Sildenafil Citrate + estradiol (NCT05951413)
- 2023-07-12Results posted on the registry: GE Healthcare, PET MPI + SPECT MPI (NCT03354273)
- 2023-07-11Results posted on the registry: National Cancer Institute (NCI), nivolumab + tadalafil (NCT03785210)
- 2023-06-26Phase 3 first posted: Mezzion Pharma Co. Ltd, Udenafil + Placebo (NCT05918211)
- 2023-06-26Also stopped (withdrawn): University of New Mexico, Sildenafil (NCT00793338)
- 2023-06-09Phase 3 first posted: Tanta University, Doxycyclin + Pentoxifylline (NCT05897034)
- 2023-05-06Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tadalafil + Placebo (NCT05844462)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision